Patch with improved release liner system
By employing flexible patch arrangement and perforated pattern design, the problem of high risk of damage and contact during the application of adhesive dressings or patches is solved, enabling rapid and accurate positioning and stable adhesion, thus improving the user experience and effectiveness of the patches.
Patent Information
- Application Number
- CN202610211649.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-12-30
- Filing Date
- 2017-12-29
- Publication Date
- 2026-05-12
AI Technical Summary
Existing adhesive dressings or patches are easily damaged during application and pose a high risk of contact to the applicator. They are also difficult to quickly and accurately target the skin area, especially for small and thin skin patches.
The flexible patch arrangement includes a flexible backing and a therapeutic adhesive composition. The backing can be divided into two parts, and the perforated pattern or slit design allows the patch to be quickly and accurately positioned on the skin, reducing the risk of fingers coming into contact with the adhesive.
It enables rapid application and accurate positioning of adhesive dressings or patches, reduces the risk of damage during application, and improves the stability and aesthetics of the patch on the skin.
Smart Images

Figure CN122005212A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application number 201780081812.5. Technical Field
[0002] This invention relates to a patch comprising an improved anti-adhesion liner system for treating various skin conditions. The improved anti-adhesion liner system allows for rapid application of the patch to the skin while minimizing the risk of damage to the patch during the process, and also minimizes the contact of the person applying the patch during application. Background Technology
[0003] Adhesive dressings or patches are used to cover and treat various skin conditions such as scratches, wounds, insect bites, acne, eczema, herpes, and warts, and can also be used to conceal irregularities while treating skin conditions.
[0004] Furthermore, the chosen adhesive dressings or patches (such as those containing hydrogels or hydrocolloids) promote a moist environment and, in themselves, facilitate the healing of the skin condition. This healing effect can be further enhanced by incorporating various active ingredients.
[0005] Given the often sensitive nature of skin areas and the optimal therapeutic benefits achieved through proper placement of dressings or patches, there has always been a need to improve the ease and reproducibility of applying adhesive dressings or patches to target skin areas. This invention addresses this need by employing an improved anti-adhesion liner system that enables rapid and consistently accurate positioning of adhesive dressings or patches to the target skin area with minimal problems. The improved anti-adhesion system is particularly effective when combined with small, thin skin patches that previously lacked anti-adhesion systems and mechanisms to prevent the patches from folding or bending on themselves, allowing for minimal contact of the adhesive with the applicator's fingers during application. Summary of the Invention
[0006] One aspect of the present invention is a flexible patch arrangement comprising: (i) a flexible patch including: a backing having two sides; and a therapeutic adhesive composition coated on at least a portion of one side of the backing. The therapeutic adhesive composition is capable of adhering to the skin of a mammal; (ii) a liner that completely covers the adhesive composition, wherein the liner includes a tool for easily dividing the liner into two parts, each part being in contact with the adhesive composition.
[0007] In one exemplary embodiment, the tool used for separation is a perforated pattern, or a slit that partially or completely penetrates the lining.
[0008] In one exemplary embodiment, the two portions of the lining are of different sizes.
[0009] In one exemplary implementation, the two portions of the lining are substantially similar in size.
[0010] In one exemplary embodiment, the area of the lining is larger than the area of the adhesive composition. In various specific embodiments, the adhesive composition covers 10 to 100% of the surface area of the lining, for example 20 to 100%, 25 to 100%, 30 to 100%, 35 to 100%, 40 to 100%, 45 to 100%, 50 to 100%, 60 to 100%, 70 to 100%, 80 to 100%, and 90 to 100%.
[0011] In one exemplary embodiment, the lining comprises one or more of polyester film, polyolefin film, siliconized paper, and plastic laminate.
[0012] In one exemplary embodiment, the lining has a thickness of about 0.01 to about 0.5 mm, for example, 0.01 to 0.4 mm, for example, about 0.01 to 0.3 mm, for example, 0.05 to 0.5 mm, for example, 0.05 to 0.3 mm.
[0013] In one exemplary embodiment, the backing is porous and / or permeable. In another embodiment, the backing is closed. In a specific embodiment, the closed backing achieves a moisture vapor transmission rate (MVTR) of <100 g / m³. 2 / 24h. In another embodiment, the backing is waterproof and breathable and achieves an MVTR > 500 g / m². 2 / 24h.
[0014] In one exemplary embodiment, the thickness of the backing is from about 0.02 to about 1.0 mm, for example from about 0.04 to about 1.0 mm, for example from about 0.05 to about 1.0 mm, for example from about 0.02 to about 0.8 mm, for example from about 0.02 to about 0.5 mm, for example from about 0.05 to about 0.3 mm.
[0015] In one exemplary embodiment, the backing comprises polycellulose fibers, polyester fibers, polyurethane fibers, polyolefin fibers, polyamide fibers, cotton fibers, copolyester fibers, or any mixture thereof. In another exemplary embodiment, the backing comprises a polycellulose film, a polyurethane film, a polyester film, a polyethylene film, a polyolefin film, or any mixture thereof.
[0016] In one exemplary embodiment, the therapeutic adhesive composition is a pressure adhesive composition and may contain one or more of polyacrylamide, xanthan gum, guar gum, hydrocolloid, starch, vinyl acetate copolymer, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene oxide, polyacrylate, polymaleic acid, polymaleic anhydride, polyurethane, polyurea, maltodextrin, carboxymethyl cellulose, and carboxypropyl cellulose.
[0017] In one exemplary embodiment, the therapeutic adhesive composition comprises one or more of hydrogels, polyurethane gels, hydrocolloids, acrylics, rubbers, and silicone gels.
[0018] Exemplary hydrocolloids include, but are not limited to, alginate and its salts, chitin, chitosan, pectin, cellulose and cellulose derivatives (e.g., cellulose ethers or cellulose esters), linked or cross-linked carboxyl or hydroxyalkyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, agar, and gelatin.
[0019] Other exemplary hydrocolloids include, but are not limited to, polyacrylates or their salts that can be further used as hydrocolloids, wherein the polyacrylates may be present as homopolymers, copolymers or block polymers.
[0020] In one exemplary embodiment, the therapeutic adhesive composition has a thickness of about 0.01 to about 1.5 mm, for example about 0.03 to about 1.2 mm, for example about 0.05 to about 1.0 mm, for example about 0.1 to about 1.0 mm, for example about 0.3 to about 1.0 mm, for example about 0.5 to about 1.0 mm.
[0021] In one exemplary embodiment, the therapeutic adhesive composition includes a topical acne agent, a wart remover, a cold sore agent, an agent for treating psoriasis, an agent for treating dermatitis (such as atopic dermatitis (eczema), seborrheic dermatitis, contact dermatitis, allergic contact dermatitis (ACD), irritant contact dermatitis (ICD)), a free radical scavenger, a moisturizer, a wrinkle reducer, or any combination thereof.
[0022] In one exemplary embodiment, the topical acne agent is selected from salicylic acid, resorcinol, benzoyl peroxide, sulfur, retinol, retinal, retinoic acid, alpha hydroxy acid, vitamin C, vitamin A, hyaluronic acid, vegetable oil, coconut oil, jojoba oil, avocado oil, olive oil, hemp oil, peptides, corticosteroids, pharmaceutically acceptable salts of any of the foregoing, and any combination thereof.
[0023] In one exemplary embodiment, the amount of the topical acne agent is from about 0.05 to about 10% by weight of the therapeutic adhesive composition, for example, 0.1 to 10% by weight, for example, 0.5 to 10% by weight, for example, 1.0 to 10% by weight, for example, 0.05 to 5% by weight, for example, 0.1 to 5% by weight, for example, 0.5 to 5% by weight, for example, 1.0 to 5% by weight.
[0024] In one exemplary embodiment, the therapeutic adhesive composition further comprises water, alcohol, or a combination thereof.
[0025] In one exemplary embodiment, the alcohol is glycerol, bisabolol, polyethylene glycol, propylene glycol, ethylene glycol, or a mixture thereof.
[0026] In one exemplary embodiment, the therapeutic agent includes a skin conditioning agent.
[0027] In one exemplary embodiment, the therapeutic agent comprises an antibiotic.
[0028] In one exemplary embodiment, the therapeutic agent comprises a preservative.
[0029] In one exemplary embodiment, the therapeutic adhesive composition is thicker at the center than at the edges. In a specific embodiment, the thickness at the edges is 0.10 to 0.80, for example 0.2 to 0.7, for example 0.1 to 0.5, for example 0.3 to 0.5, of the center thickness.
[0030] In one exemplary embodiment, the backing and the therapeutic adhesive composition have a circular, triangular, rectangular, square, or elliptical shape, etc.
[0031] In one exemplary implementation, the lining and patch are different colors.
[0032] In one exemplary embodiment, the patch arrangement is encapsulated in a sealed package.
[0033] In one exemplary embodiment, the arrangement is encapsulated in sealing paper or poly / plastic packaging material, or a combination thereof.
[0034] In one exemplary embodiment, the adhesive and the packaging material are sterilizable or sterilizable.
[0035] In one exemplary embodiment, the diameter of the backing is 0.1 to 5 inches, for example 0.5 to 5 inches, for example 1 to 5 inches, for example 2 to 5 inches, for example 0.1 to 3 inches, for example 0.1 to 2 inches, for example 0.2 to 1 inch, for example 0.2 to 0.5 inches.
[0036] Another aspect of the invention is a method of attaching a patch described herein to a target skin region of a mammal in need, the method comprising: separating one of two portions of a liner from the patch arrangement to expose a first portion of the adhesive composition of the patch; attaching the exposed first portion of the adhesive composition to the target skin region; separating a second of the two portions of the liner from the patch arrangement to expose a remaining portion of the adhesive composition of the patch while the exposed first portion of the adhesive composition remains attached to the target skin region; and attaching the exposed remaining portion of the adhesive composition to completely attach the patch to the target skin region.
[0037] In one exemplary implementation, the mammal is a human.
[0038] In one exemplary implementation, the target skin area is the face, neck, shoulder, chest, back, elbow, inner elbow, or any combination thereof.
[0039] In one exemplary embodiment, the patch is attached to the target skin area for about 10 minutes to about 72 hours, for example, about 30 minutes to about 72 hours, for example, about 1 to about 72 hours, for example, about 6 to about 72 hours, for example, about 12 to about 72 hours, for example, about 24 to 72 hours, for example, about 1 to about 48 hours, for example, about 6 to about 48 hours, for example, about 12 to about 48 hours, for example, about 24 to 48 hours, for example, about 1 to about 24 hours, for example, about 3 to about 24 hours, for example, about 6 to about 24 hours, for example, about 12 to 24 hours.
[0040] In one exemplary embodiment, the tool for separation is a perforated pattern, or a slit that partially or completely penetrates the lining.
[0041] Another aspect of the invention is a method for treating or preventing skin diseases or conditions in mammals in need, comprising applying a patch as described herein to the affected skin surface for a period of time to effectively treat or prevent the skin disease or condition.
[0042] In one exemplary implementation, the disease or condition is selected from acne, warts, cold sores (herpes labialis), atopic dermatitis, seborrheic dermatitis, contact dermatitis, allergic contact eczema, psoriasis, herpes zoster, urticaria, insect bites, age spots (freckles or sunspots), and wrinkles.
[0043] In one exemplary implementation, the disease is acne vulgaris.
[0044] Another aspect of the invention is a sheet comprising a plurality of patch arrangements arranged in parallel as described herein, wherein a slit or perforation pattern present in each patch arrangement forms a single uninterrupted line extending the length or width of the sheet.
[0045] In one exemplary embodiment, each patch arrangement is separated from adjacent patch arrangements by different easily separable perforated patterns or slits.
[0046] In one exemplary embodiment, each different perforation pattern or slit cumulatively forms a single uninterrupted line that extends the length or width of the sheet. Attached Figure Description
[0047] The following figures illustrate specific embodiments of the invention and are not intended to otherwise limit the scope of the invention described herein.
[0048] Figure 1 A top view of a specific packaged array of 10 circular patches is shown, wherein a single longitudinal (vertical) perforation line and four transverse (lateral) perforation lines allow the array to be separated into 10 individual patches. The single perforation line running beneath each patch allows for the gradual removal of the release liner from the patch's therapeutic adhesive layer, representing an improved process for applying patches to the skin according to one aspect of the invention.
[0049] Figure 2 yes Figure 1 A top view of the array, which clearly shows the perforation lines required to separate individual patches from an array of 10 patches, as well as individual perforation lines located below each patch, which allow for the gradual removal of the anti-adhesive liner from the therapeutic adhesive layer of the patch.
[0050] Figure 3 yes Figure 1 The rear view of the array shows the anti-stick lining and perforated lines.
[0051] Figure 4 This is a side view of a specific packaged array of patches, which identifies the backing and therapeutic adhesive composition components of each patch, as well as the release liner in contact with the therapeutic adhesive composition layer.
[0052] Figure 5 A two-step process for applying the patch is described, which facilitates precise positioning of the patch to the target skin area, with minimal fingering of the therapeutic adhesive layer and minimal risk of the patch undesirably folding or bending onto itself. Detailed description Backing layer The backing layer may comprise any suitable material known for preparing wound dressings, including but not limited to foam, polyurethane, polyethylene, polyester, polyamide, polycellulose, cotton, or any mixture thereof. In one exemplary embodiment, the backing is flexible, resilient, and / or stretchable. In one exemplary embodiment, the backing comprises two sides, a front and a back. In one exemplary embodiment, the backing layer is vapor or moisture permeable and capable of achieving an MVTR > 300 g / m³. 2 / 24h, but the liquid is impermeable. In one exemplary embodiment, the backing layer is continuous (e.g., without pores, perforations, or dents) or discontinuous (e.g., containing pores, perforations, or dents). In one exemplary embodiment, the backing contains a hydrophobic sizing agent.
[0053] The backing layer has a thickness suitable for its intended use. In one exemplary embodiment, the thickness of the backing layer is from 0.02 to 1.0 mm, for example from 0.03 to 0.8 mm, for example from about 0.05 to 0.6 mm, for example from about 0.07 to 0.5 mm, for example from about 0.1 to 0.5 mm.
[0054] Therapeutic adhesive composition The therapeutic adhesive compositions of the present invention comprise or consist of any skin-friendly adhesive compositions known for use in medical articles for contact with mammalian (e.g., human) skin. Exemplary adhesive compositions may suitably be, but are not limited to, those disclosed in U.S. Patents US2013 / 0152944, 2011 / 0105977, 6,495,158, and 9,078,948.
[0055] In one exemplary embodiment, the therapeutic adhesive composition is a pressure-sensitive therapeutic adhesive composition that may include one or more of the following: polyacrylamide, xanthan gum, guar gum, hydrocolloid, starch, vinyl acetate copolymer, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene oxide, polyacrylate, polymaleic acid, polymaleic anhydride, polyurethane, polyurea, maltodextrin, carboxymethyl cellulose, polyisobutylene, rubber, polybutene, carboxypropyl cellulose, polydimethylsiloxane, polystyrene-butadiene-polystyrene, polystyrene-polyisoprene-polystyrene, polystyrene-poly(ethylene-butene)-polystyrene block polymer, or any combination thereof.
[0056] In one exemplary embodiment, the therapeutic adhesive composition comprises a topical acne agent, such as, but not limited to, salicylic acid, resorcinol, resorcinol acetate, benzoyl peroxide, sulfur, retinol, retinal, retinoic acid, alpha-hydroxy acid, vitamin C, vitamin A, hyaluronic acid, vegetable oil, coconut oil, jojoba oil, avocado oil, olive oil, hemp oil, peptides (e.g., glycyl-histyl-lysine (GHK)-Cu and palmitoyl KTTKS), corticosteroids, any of the aforementioned pharmaceutically acceptable salts, or any combination thereof. In one exemplary embodiment, the topical acne agent is salicylic acid or a pharmaceutically acceptable salt thereof. In one exemplary embodiment, the presence of salicylic acid or a pharmaceutically acceptable salt thereof is from about 0.05 to about 10% by weight of the adhesive composition, including the more specific range described herein.
[0057] In one exemplary embodiment, the adhesive composition comprises a solvent, which includes, but is not limited to, alcohols (such as polyols), water, or combinations thereof. In one exemplary embodiment, the polyol is propylene glycol, ethylene glycol, glycerol, or combinations thereof. In one exemplary embodiment, the solvent is present in an amount of about 0.5 to about 25% by weight of the adhesive composition, for example, about 1 to about 15% by weight, for example, about 5 to about 15% by weight, for example, about 10 to about 25% by weight.
[0058] In one exemplary embodiment, the adhesive composition is located on the entire surface of the backing. In one exemplary embodiment, the adhesive composition is located on only a portion of the entire surface of the backing. In one exemplary embodiment, the adhesive composition is adhered to or coated only on the surface of the backing. In one exemplary embodiment, the adhesive composition is partially embedded in at least a portion of the backing, ranging from about 50% to 100%, for example, about 60% to 100%, for example, about 70% to 100%, for example, about 80% to 100%, for example, about 90% to 100%.
[0059] In one exemplary embodiment, the adhesive composition comprises at least one of glycerin, pectin, skin conditioning agents (e.g., vitamin E, aloe vera, lanolin, calamine, or any combination thereof), antimicrobial agents (e.g., antifungal agents), preservatives (e.g., iodine, triclosan, silver, chlorhexidine, chlorhexidine salt, PHMB, and / or oxytinidin), antibiotics (e.g., erythromycin, tetracycline, or cephalosporins), carotenoids, analgesics, and hemostatic agents, in an amount of about 0.01 to about 50% by weight of the adhesive composition, for example, about 0.1 to 50% by weight, for example, about 1 to 50% by weight, for example, about 5 to about 50% by weight, for example, about 10 to about 50% by weight, for example, about 20 to about 50% by weight.
[0060] In one exemplary embodiment, the thickness of the adhesive composition is from 0.01 mm to about 1.5 mm, for example from about 0.10 to about 0.60 mm, for example from about 0.20 to about 0.50 mm, including other ranges described herein.
[0061] In one exemplary embodiment, multiple patches (e.g., 2, 4, 6, 8, 10, 12, or 16) can be secured or mounted on the release liner. In one exemplary embodiment, the patches are crescent-shaped, rectangular, circular, or elliptical.
[0062] In one exemplary embodiment, the patch or backing has a diameter of about 0.1 to about 5 inches, for example about 0.2 to about 2 inches, for example about 0.3 to about 1 inch, for example about 0.3 to about 0.5 inches, including other ranges described herein.
[0063] In one exemplary embodiment, the present invention also provides a method for treating or preventing acne, dermatitis, or warts in a mammal (e.g., a human) by applying the patch to a target skin surface for a period of time. In one exemplary embodiment, the target skin surface of the mammal is the face, neck, shoulders, chest, back, or any combination thereof. In one exemplary embodiment, the effective time is from about 10 minutes to about 72 hours, including the more specific range described herein.
[0064] In one exemplary embodiment, the patch according to the invention is applied to the lips of a mammal to prevent or treat cold sores. Applying the patch to the lips may include applying only to the lip area, or a portion of the patch may be applied to the lips (e.g., the edge of the lips) and the remainder of the patch may be applied to the surrounding skin.
[0065] The thickness of the adhesive composition layer of the patch of the present invention can be substantially constant on the surface or on the adhesive composition layer, or alternatively, the adhesive composition layer can have a thicker portion at the center of the composition compared to the edge of the composition layer—that is, a beveled edge, wherein in various specific embodiments, the thickness of the edge is 10% or 20% or 50% or 75% of the thickness of the center.
[0066] Any suitable amount of pressure-sensitive adhesive may be present in the therapeutic adhesive composition, provided that the amount of pressure-sensitive adhesive effectively provides the necessary adhesion to the backing and / or lining and remains stable in the therapeutic adhesive composition over a prolonged period of time. Typically, the therapeutic adhesive composition may comprise from about 0.01 to about 99.99% by weight of pressure-sensitive adhesive, for example, from about 0.1 to about 99.9% by weight, for example, from about 1 to about 99% by weight, for example, from about 2 to about 98% by weight, for example, from about 3 to about 97% by weight, for example, from about 5 to about 95% by weight, for example, from about 10 to about 90% by weight, for example, from about 15 to about 85% by weight, for example, from about 20 to about 80% by weight, for example, from about 25 to about 75% by weight, for example, from about 30 to about 70% by weight, for example, from about 40 to about 60% by weight.
[0067] As used herein, “acne” refers to inflammatory follicles, papules, or pustules involving sebaceous glands. Types of acne include acne conglobata, chloracne, and rosacea. See, for example, Stedman's Medical Dictionary, 25th edition, Williams & Wilkins, Baltimore, Md., pp. 15-16 (1990).
[0068] The patch of the present invention can be applied to any suitable skin surface of a subject in need. Suitable skin surfaces to which the patch can be applied include the face, neck, shoulders, chest, elbows, inner elbows, and back. In one exemplary embodiment, the patch of the present invention is applied to the face (including the lips) of a subject.
[0069] The patches of this invention are also used for cosmetically covering prominent skin blemishes, such as acne and / or papules. Many commercially available products cannot effectively cover the entire skin blemish for a long time, but the patches of this invention can achieve treatment of skin blemishes for more than 4 hours, for example, more than 8 hours, for example, more than 12 hours, for example, more than 24 hours, for example, more than 48 hours.
[0070] Anti-stick lining The release liner in the patch arrangement of the present invention is an adhesive composition used to coat and protect the patch, preventing the surface of the adhesive composition from being contaminated before attachment. The release liner is temporarily attached to the adhesive composition in an easily removable state, typically requiring only a peel force to separate.
[0071] Suitable compositions for the anti-stick liner of the present invention include those commonly known for use with skin-friendly adhesive compositions, such as anti-stick liners prepared by a siloxane release treatment of the surface of a plastic sheet or polyolefin film (such as polyethylene or polypropylene or a laminate of plastic film and paper). In one exemplary embodiment, the thickness of the anti-stick liner has a thickness of about 0.01 to about 1.0 mm, for example about 0.03 to about 0.7 mm, for example about 0.07 to about 0.5 mm, for example about 0.1 to about 0.4 mm, including other ranges described herein.
[0072] In one exemplary embodiment, the area of the release liner is larger than the area of the patch—that is, the area of the backing and adhesive composition combination.
[0073] In an exemplary embodiment where the release liner is larger than the patch, the portion of the release liner extending beyond the patch can be held (grasped) and peeled from the therapeutic adhesive composition using the fingers of one hand to separate the release liner from the therapeutic adhesive composition. In one exemplary embodiment, the release liner covering the therapeutic adhesive composition includes a perforated pattern or slits that allow easy separation (peeling) of the liner (both parts) from the therapeutic adhesive composition. In this embodiment, the patch is attached to the skin of a mammal in need in a two-step process, wherein in a first step, one of the two parts of the liner is peeled off, exposing a portion of the therapeutic adhesive composition, which is then attached (secured) to the desired area of the mammalian skin. In a second step, a second (remaining) portion of the liner is peeled off, while the patch remains attached to the subject's skin through the previously exposed portion of the therapeutic adhesive composition, thereby exposing the remaining portion of the therapeutic adhesive composition, which is then attached (adheded) to the subject's skin. This tandem pattern of patches applying the present invention allows for rapid and substantially error-free application of the patch to the subject's skin while minimizing adverse events such as undesirable adhesion of a portion of the adhesive composition to another portion of the patch. This type of incident prevents the therapeutic adhesive composition from making full contact with the skin, which reduces the therapeutic benefits of the patch and undesirably makes the patch less noticeable on the subject's skin surface due to its lack of a completely flat surface.
[0074] Slits and / or perforations In one exemplary embodiment, a cut forming a cutting line in a single patch of the invention divides the release liner into two parts, thereby allowing the patch to be applied in series (two steps) to the skin of a mammalian subject. In one exemplary embodiment, the liner is cut to a depth of at least 10%, such as 15%, 20%, 30%, 40%, 50%, 60%, 70%, or up to 100% of the liner thickness to allow easy removal of the liner from the therapeutic adhesive composition.
[0075] Besides straight lines, cutting lines can be any shape that allows the lining to be easily divided into multiple sections. For example, the shape can be a curve, a zigzag line, an arc, a wave, or a zigzag.
[0076] In one exemplary embodiment, the liner is perforated to facilitate the application of the patch in series (two steps) to the skin of a mammalian subject. Besides straight lines, the perforations can be any shape that allows the liner to be easily divided into multiple sections. For example, the shape can be a curve, a zigzag line, an arc, a wave, or a zigzag.
[0077] In one exemplary embodiment, the improved anti-stick lining system comprises a combination of one or more perforated lines and one or more slits.
[0078] The patch arrangement of the present invention is suitable for medical and cosmetic applications.
[0079] Example The following non-limiting exemplary formulations illustrate the use of suitable adhesive compositions in combination with therapeutic agents in the therapeutic adhesive compositions of the present invention.
[0080] Example 1 (a) 5 to 20% by weight, or 5 to 15% by weight, or 10 to 15% by weight of elastomer; (b) 1 to 10% by weight, or 2 to 10% by weight, or 5 to 10% by weight of mineral oil plasticizer; (c) 20 to 60% by weight, or 25 to 55% by weight, or 30 to 55% by weight, or 35 to 50% by weight of a tackifier; and (d) 20 to 60% by weight, or 25 to 50% by weight, or 30 to 50% by weight, or 30 to 45% by weight of absorbent, wherein the total weight percentage of components (a) to (d) is 100%.
[0081] In an exemplary embodiment of the formulation described in Example 1, the elastomer is selected from Kraton SEBS, Kraton SIS, Kraton SBS, and mixtures thereof; the mineral oil plasticizer is selected from mineral oil, vegetable oil, hydrogenated vegetable oil, and mixtures thereof; the tackifier is selected from acrylic resin, C5 tackifier, hydrogenated hydrocarbon resin, and mixtures thereof; the absorbent is selected from carboxymethyl cellulose, gelatin, SAP superabsorbent, and mixtures thereof. The therapeutic agent is one or more of benzoyl peroxide, salicylic acid, glycolic acid, and sulfur.
[0082] Example 2 (a) 10 to 15% by weight of mineral oil; (b) 25 to 50% by weight, or 30 to 40% by weight, of carboxymethyl cellulose; (c) 3 to 15% by weight, or 5 to 10% by weight of KRATON ® 1161; and (d) 25 to 45% by weight, or 30 to 40% by weight of ARKON ® P115, The total weight percentage of components (a) to (d) is 100%.
[0083] Example 3 (a) 3 to 10% by weight, or 5 to 10% by weight, of mineral oil; (b) 25 to 50% by weight, or 30 to 40% by weight, of carboxymethyl cellulose; (c) 10 to 25% by weight, or 15 to 20% by weight of KRATON ® 1161; and (d) 25 to 55% by weight, or 35 to 45% by weight of FORAL ® 85, The total weight percentage of components (a) to (d) is 100%.
[0084] Example 4. (a) 35 to 65% by weight, or 45 to 55% by weight, of mineral oil; and (b) 35 to 65% by weight, or 45 to 55% by weight, carboxymethyl cellulose, The total weight percentage of components (a) and (b) is 100%.
[0085] Example 5. (a) 20 to 45% by weight, or 30 to 40% by weight, of α-linolenic acid; (b) 15 to 40% by weight, or 20 to 35% by weight, of carboxymethyl cellulose; (c) 20 to 45% by weight, or 25 to 40% by weight of KRATON ® ;and (d) 10 to 25% by weight, or 15 to 20% by weight of FORAL ® 85, The total weight percentage of components (a) to (d) is 100%.
[0086] Example 6. (a) 1 to 15% by weight, or 5 to 10% by weight, myristic acid; (b) 20 to 50% by weight, or 30 to 40% by weight, of carboxymethyl cellulose; (c) 10 to 30% by weight, or 15 to 25% by weight of KRATON ® ;and (d) 20 to 55% by weight, or 35 to 50% by weight of FORAL ® 85, The total weight percentage of components (a) to (d) is 100%.
[0087] Example 7. (a) 20 to 45% by weight, or 25 to 40% by weight, of mineral oil and a 1:1:1 mixture of α-linolenic acid and myristic acid; (b) 10 to 35% by weight, or 15 to 30% by weight, of carboxymethyl cellulose; (c) 15 to 40% by weight, or 25 to 40% by weight, of KRATON ® ;and (d) 10 to 30% by weight, or 15 to 25% by weight of FORAL ® 85, The total weight percentage of components (a) to (d) is 100%.
[0088] Example 8. (a) 35 to 65% by weight, or 40 to 55% by weight, of a 1:2:1 mixture of mineral oil and α-linolenic acid and myristic acid; (b) 15 to 40% by weight, or 20 to 35% by weight, of carboxymethyl cellulose; (c) 5 to 30% by weight, or 5 to 20% by weight of KRATON ® ;and (d) 1 to 20% by weight, or 10 to 15% by weight of FORAL ® 85, The total weight percentage of components (a) to (d) is 100%.
[0089] All patents and other publications cited in this article are incorporated herein by reference in their entirety.
Claims
1. A flexible patch arrangement, comprising the following in order: Flexible patches, including: The backing is double-sided, and is waterproof and breathable with an MVTR > 500 g / m². 2 / 24h; and A therapeutic adhesive composition coated on the entire surface of the backing, wherein the therapeutic adhesive composition is capable of adhering to mammalian skin and comprises one or more of hydrocolloids and hydrogels, the therapeutic adhesive composition being in the form of a layer, and having a thicker portion at the center of the composition layer compared to its edges; and An anti-adhesive liner that completely covers the adhesive composition, wherein the anti-adhesive liner includes a tool for easily dividing the liner into two parts, each part being in contact with the adhesive composition, wherein the tool for dividing the anti-adhesive liner into two parts is a perforated pattern or slit that partially or completely penetrates the anti-adhesive liner, wherein the area of the anti-adhesive liner is larger than the area of the flexible patch to form a gripping portion; The flexible patch has a circular or elliptical shape and a diameter of 0.2 inches to 0.5 inches (5.08 mm to 12.7 mm).
2. The flexible patch arrangement of claim 1, wherein the therapeutic adhesive composition further comprises a topical acne agent.
3. The patch arrangement according to claim 1, wherein the two portions of the liner are of different sizes.
4. The patch arrangement according to claim 1, wherein the two portions of the liner are substantially similar in size.
5. The patch arrangement according to claim 1, wherein the lining and the patch are of different colors.
6. The patch arrangement according to claim 1, wherein the arrangement is encapsulated in a sealed package.
7. The patch arrangement according to claim 1, wherein the arrangement is encapsulated in sealing paper or poly / plastic packaging material, or a combination thereof.
8. The patch arrangement according to claim 7, wherein the adhesive and packaging material are sterilizable.
9. The patch arrangement according to claim 1, wherein the liner comprises one or more of polyester film, polyolefin film, siliconized paper, or plastic laminate.
10. The patch arrangement of claim 1, wherein the liner has a thickness of about 0.01 to about 0.5 mm.
11. The patch arrangement of claim 1, wherein the backing is porous.
12. The patch arrangement according to claim 1, wherein the backing is closed.
13. The patch arrangement according to claim 1, wherein the thickness of the backing is from about 0.02 mm to about 1.0 mm.
14. The patch arrangement according to claim 1, wherein the thickness of the backing is from about 0.05 mm to about 0.3 mm.
15. The patch arrangement according to claim 1, wherein the backing comprises a polycellulose film, a polyurethane film, a polyester film, a polyethylene film, a polyolefin film, or any mixture thereof.
16. The patch arrangement according to claim 1, wherein the therapeutic adhesive composition comprises one or more hydrocolloids selected from: alginate and its salts, chitin, chitosan, pectin, cellulose ethers, cellulose esters, carboxyalkyl cellulose, hydroxyalkyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, agar and gelatin, xanthan gum, guar gum, hydrocolloids, starch, vinyl acetate copolymer, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene oxide, polyacrylate, polymaleic acid, polymaleic anhydride, polyurethane, polyurea, maltodextrin, carboxymethyl cellulose and carboxypropyl cellulose.
17. The patch arrangement according to claim 1, wherein the therapeutic adhesive composition comprises one or more of carboxymethyl cellulose and carboxypropyl cellulose.
18. The patch arrangement according to claim 1, wherein the therapeutic adhesive composition has a thickness of about 0.01 mm to about 1.5 mm.
19. The patch arrangement of claim 1, wherein the therapeutic adhesive composition comprises a topical acne agent, wherein the topical acne agent is selected from the group consisting of salicylic acid, resorcinol, benzoyl peroxide, sulfur, retinol, retinal, retinoic acid, alpha-hydroxy acid, vitamin C, vitamin A, hyaluronic acid, vegetable oil, coconut oil, jojoba oil, avocado oil, olive oil, hemp oil, peptides, corticosteroids, any pharmaceutically acceptable salt of the foregoing, and any combination thereof.
20. The patch arrangement of claim 19, wherein the amount of the topical acne agent is from about 0.05% by weight to about 10% by weight of the therapeutic adhesive composition.
21. The patch arrangement of claim 1, wherein the therapeutic adhesive composition further comprises water, alcohol, or a combination thereof.
22. The patch arrangement according to claim 21, wherein the alcohol is glycerol, bisabolol, polyethylene glycol, propylene glycol, ethylene glycol, or a mixture thereof.
23. The patch arrangement according to claim 1, wherein the therapeutic agent comprises a skin conditioning agent.
24. The patch arrangement of claim 1, wherein the therapeutic agent comprises an antibiotic or a preservative.
25. A patch arrangement for treating acne, wherein the patch arrangement is as described in claim 2.
26. A sheet comprising a plurality of patch arrangements as described in claim 1 arranged in parallel, wherein a slit or perforation pattern present in each patch arrangement forms a single uninterrupted line extending the length or width of the sheet.
27. The sheet of claim 26, wherein each patch arrangement is separated from the adjacent patch arrangement by different easily separable perforated patterns or slits.
28. The sheet of claim 27, wherein each different perforation pattern or slit cumulatively forms a single uninterrupted line, the single uninterrupted line extending the length or width of the sheet.
